Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.

Dempster DW, Cosman F, Zhou H, Nieves JW, Bostrom M, Lindsay R

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research21 Mar 2016Cited by 29 (Europe PMC)

PMID26916877DOI10.1002/jbmr.2822PepBankPUB-26916877

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In treatment-naive women, teriparatide increased bone formation indices at both biopsy times.
In plain wordsIn women without prior treatment, teriparatide increased bone formation indices at both biopsy times.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation indices in treatment-naive subjects
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
Both Rx-Naïve and ALN-RX subjects responded to TPTD with significant increases in bone formation indices at both time points.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
Report a problemFND-2691687701
02HumanNon-randomized trialEfficacy outcome
In treatment-naive women, daily teriparatide produced higher cancellous bone formation rates than cyclic treatment at 7 months.
In plain wordsIn women without prior treatment, daily teriparatide increased cancellous bone formation more than cyclic treatment at 7 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCancellous bone formation: daily versus cyclic
Study
n: not reported in source
Comparator
cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
However, in Rx-Naïve patients, bone formation rate (BFR/BS) was higher in patients receiving daily treatment compared with those receiving cyclic TPTD treatment in all three envelopes in the 7-month biopsies.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
Report a problemFND-2691687705
03HumanNon-randomized trialEfficacy outcome
In treatment-naive women, daily teriparatide produced higher endocortical bone formation rates than cyclic treatment at 7 months.
In plain wordsIn women without prior treatment, daily teriparatide increased endocortical bone formation more than cyclic treatment at 7 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseEndocortical bone formation: daily versus cyclic
Study
n: not reported in source
Comparator
cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
However, in Rx-Naïve patients, bone formation rate (BFR/BS) was higher in patients receiving daily treatment compared with those receiving cyclic TPTD treatment in all three envelopes in the 7-month biopsies.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
Report a problemFND-2691687706
04HumanNon-randomized trialEfficacy outcome
In treatment-naive women, daily teriparatide produced higher intracortical bone formation rates than cyclic treatment at 7 months.
In plain wordsIn women without prior treatment, daily teriparatide increased intracortical bone formation more than cyclic treatment at 7 months.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntracortical bone formation: daily versus cyclic
Study
n: not reported in source
Comparator
cyclic teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
However, in Rx-Naïve patients, bone formation rate (BFR/BS) was higher in patients receiving daily treatment compared with those receiving cyclic TPTD treatment in all three envelopes in the 7-month biopsies.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
Report a problemFND-2691687707
05HumanNon-randomized trialEfficacy outcome
At 7 months, treatment-naive women receiving daily teriparatide had higher cortical porosity than all other groups.
In plain wordsAt 7 months, women without prior treatment receiving daily teriparatide had more cortical porosity than all other groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical porosity
Study
n: not reported in source
Comparator
all other groups
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · injectionAs given in this study (human).
Source sentences
Summary
In the 7-month biopsies, cortical porosity was higher in the Rx-Naïve group receiving daily TPTD than in all other groups.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
Report a problemFND-2691687708

Studies that did not test the peptide alone3

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

06HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome
In women receiving ongoing alendronate, the teriparatide regimen increased bone formation indices at both biopsy times.
In plain wordsIn women receiving alendronate, the combined regimen increased bone formation indices at both biopsy times.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseBone formation indices during ongoing alendronate
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Both Rx-Naïve and ALN-RX subjects responded to TPTD with significant increases in bone formation indices at both time points.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2691687702
07HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women on cyclic teriparatide, the first and second cycles stimulated cancellous bone formation rate to a similar extent in subjects on ongoing alendronate and treatment-naive subjects.
In plain wordsIn women on cyclic teriparatide, cancellous bone formation rose to a similar extent with and without ongoing alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCancellous bone formation rate: alendronate-treated versus treatment-naive, cyclic teriparatide
Study
n: not reported in source
Comparator
treatment-naive subjects
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With cyclic TPTD treatment, the first and second cycles of TPTD stimulated bone formation rate in the cancellous and endocortical envelopes to a similar extent in ALN-Rx and Rx-Naïve subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2691687703
08HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women on cyclic teriparatide, the first and second cycles stimulated endocortical bone formation rate to a similar extent in subjects on ongoing alendronate and treatment-naive subjects.
In plain wordsIn women on cyclic teriparatide, endocortical bone formation rose to a similar extent with and without ongoing alendronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEndocortical bone formation rate: alendronate-treated versus treatment-naive, cyclic teriparatide
Study
n: not reported in source
Comparator
treatment-naive subjects
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
With cyclic TPTD treatment, the first and second cycles of TPTD stimulated bone formation rate in the cancellous and endocortical envelopes to a similar extent in ALN-Rx and Rx-Naïve subjects.
3 context sentences(design, population, supporting numbers)
Summary · context
Using quadruple tetracycline-labeled bone biopsies, we have compared the bone formation response to teriparatide (TPTD) in treatment-naïve subjects (Rx-Naïve) and in subjects on prior and ongoing alendronate (ALN) treatment (ALN-Rx).
Summary · context
TPTD was given as a standard, continuous daily injection or as a cyclic regimen (3 months on daily TPTD, 3 months off, 3 months on daily TPTD).
Summary · context
Subjects were biopsied at 7 weeks and at 7 months to allow comparison of the bone formation response to the first and second cycles of TPTD.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-2691687704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.